Barasa Benjamin, Slijper Monique
Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands; Netherlands Proteomics Centre, Padualaan 8, 3584 CH, The Netherlands.
Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands; Netherlands Proteomics Centre, Padualaan 8, 3584 CH, The Netherlands.
Biochim Biophys Acta. 2014 May;1844(5):1003-10. doi: 10.1016/j.bbapap.2013.10.002. Epub 2013 Oct 12.
Red blood cells are rather unique body cells, since they have lost all organelles when mature, which results in lack of potential to replace proteins that have lost their function. They maintain only a few pathways for obtaining energy and reducing power for the key functions they need to fulfill. This makes RBCs highly sensitive to any aberration. If so, these RBCs are quickly removed from circulation, but if the RBC levels reduce extremely fast, this results in hemolytic anemia. Several causes of HA exist, and proteome analysis is the most straightforward way to obtain deeper insight into RBC functioning under the stress of disease. This should result in discovery of biomarkers, typical for each source of anemia. In this review, several challenges to generate in-depth RBC proteomes are described, like to obtain pure RBCs, to overcome the wide dynamic range in protein expression, and to establish which of the identified/quantified proteins are active in RBCs. The final challenge is to acquire and validate suited biomarkers unique for the changes that occur for each of the clinical questions; in red blood cell aging (also important for transfusion medicine), for thalassemias or sickle cell disease. Biomarkers for other hemolytic anemias that are caused by dysfunction of RBC membrane proteins (the RBC membrane defects) or RBC cytosolic proteins (the enzymopathies) are sometimes even harder to discover, in particular for the patients with RBC rare diseases with unknown cause. This article is part of a Special Issue entitled: Biomarkers: A Proteomic Challenge.
红细胞是相当独特的体细胞,因为它们在成熟时失去了所有细胞器,这导致缺乏替换已丧失功能蛋白质的潜力。它们仅维持少数几个途径来获取能量和还原力,以实现其所需的关键功能。这使得红细胞对任何异常都高度敏感。如果出现异常,这些红细胞会迅速从循环中清除,但如果红细胞水平极速下降,就会导致溶血性贫血。溶血性贫血存在多种病因,蛋白质组分析是深入了解疾病应激下红细胞功能的最直接方法。这应该会促成发现每种贫血病因所特有的生物标志物。在本综述中,描述了生成深度红细胞蛋白质组所面临的若干挑战,比如获取纯净的红细胞、克服蛋白质表达的宽动态范围,以及确定所鉴定/定量的哪些蛋白质在红细胞中具有活性。最后的挑战是获取并验证适合于每个临床问题所发生变化的独特生物标志物;这些问题包括红细胞衰老(这对输血医学也很重要)、地中海贫血或镰状细胞病。由红细胞膜蛋白功能障碍(红细胞膜缺陷)或红细胞胞质蛋白(酶病)引起的其他溶血性贫血的生物标志物有时甚至更难发现,尤其是对于病因不明的红细胞罕见病患者。本文是名为:生物标志物:蛋白质组学挑战的特刊的一部分。